A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

Registry ID

BO42353

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

HOFFMANN-LA ROCHE LIMITED

Start date

2024-01-05

Last update

2021-02-10

Conditions

• ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

Related clinical trials

• A PHASE 3, OPEN-LABEL MULTICENTER STUDY OF ALXN1210 IN CHILDREN AND ADOLESCENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
• SINGLE ARM STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAIVE ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

View on source registry